Zepbound for Sleep Apnea: What the Approval Means

For decades, treatment for obstructive sleep apnea meant a machine, a mask and a hose. On December 20, 2024, that changed: FDA approved Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity, making it the first prescription medicine ever approved for the condition [1][2].

Two years on, plenty of people know that headline and very little of the detail. This explains who the approval actually covers, what the trials measured, why the label sets a higher dose range than it does for weight loss, and the one sentence in the prescribing information that anyone hoping to retire a CPAP machine needs to read.

This is not medical advice. Sleep apnea is diagnosed with a sleep study and managed by a clinician, and nothing here should be used to change or stop a treatment you are already on.

What exactly did FDA approve?

The indication, in the label’s own words, is to treat “moderate to severe obstructive sleep apnea (OSA) in adults with obesity,” in combination with a reduced-calorie diet and increased physical activity [1].

Every part of that sentence narrows it:

• Moderate to severe. The trials defined that as an apnea-hypopnea index of 15 or more events per hour, measured by polysomnogram.
• Obstructive. Not central sleep apnea, which has a different mechanism.
• In adults with obesity. The trials required a body mass index of at least 30. The label also states it is not known whether Zepbound is safe and effective in children.
• With diet and activity. The indication is not written as a standalone drug treatment.

The approval came through supplement S-013 to Zepbound’s original application, NDA 217806 [3]. It was the brand’s second indication in just over a year, following the November 2023 approval for chronic weight management [2].

What is the apnea-hypopnea index, and why does it matter?

The apnea-hypopnea index, or AHI, counts how many times an hour your breathing stops completely (an apnea) or becomes shallow enough to matter (a hypopnea) while you sleep. It is measured during a sleep study.

Roughly, 5 to 15 events an hour is mild, 15 to 30 is moderate, and above 30 is severe. It is the number the sleep apnea trials were built around, and it is how the label reports the results.

The people in these trials were not borderline cases. Average baseline AHI was 51.5 events an hour in one study and 49.5 in the other — well into the severe range — and roughly two thirds of participants had severe disease [1].

What did the trials actually show?

The approval rests on SURMOUNT-OSA, a master protocol trial (NCT05412004) containing two separate 52-week randomized, double-blind, placebo-controlled studies in a combined 469 adults [1]. Both required moderate-to-severe OSA and a BMI of at least 30, and both excluded people with type 2 diabetes. Everyone received counseling on a reduced-calorie diet and increased physical activity.

The split between the two studies is the interesting part:

• Study 5 enrolled 234 adults who were unable or unwilling to use positive airway pressure (PAP) therapy. Mean age 48, 67 percent male.
• Study 6 enrolled 235 adults who were on PAP therapy and planned to stay on it. Mean age 52, 72 percent male. For the purposes of measuring the primary endpoint, they suspended PAP for seven days.

Zepbound doses were escalated over up to 20 weeks to a maximum tolerated dose of 10 mg or 15 mg once weekly.

The results at 52 weeks, straight from the label [1]:

	Study 5 (no PAP)		Study 6 (on PAP)
	Placebo	Zepbound	Placebo	Zepbound
Baseline AHI (events/hour)	50.1	52.9	53.1	46.1
Change in AHI	-5.3	-25.3	-5.5	-29.3
Percent change in AHI	-3.0%	-50.7%	-2.5%	-58.7%
At least 50% AHI reduction	19%	61.2%	23.3%	72.4%
Remission or mild non-symptomatic OSA	15.9%	42.2%	14.3%	50.2%
Change in body weight	-1.6%	-17.7%	-2.3%	-19.6%

Every one of those Zepbound-versus-placebo differences was statistically significant with a p-value below 0.001 [1].

Two more findings from the same studies. Sleep apnea-specific hypoxic burden — a measure of how much oxygen you lose overnight — fell substantially more on Zepbound in both studies. And in both studies, people on Zepbound had greater reductions in systolic blood pressure and in high-sensitivity C-reactive protein, a marker of inflammation, than people on placebo [1].

Participants also reported improvement in sleep-related impairment, measured with a standard patient-reported questionnaire [1].

In its announcement, Lilly translated the numbers for a general audience: Zepbound was about five times more effective than placebo at reducing breathing disruptions in adults not on PAP, and average weight loss was 45 pounds without PAP and 50 pounds with it [2].

Why does the sleep apnea dose start at 10 mg?

Because the label says so, and because that is what the trials used.

The escalation is identical to weight management: 2.5 mg once weekly for four weeks, then 5 mg, then increases of 2.5 mg after at least four weeks on the current dose. The maximum is 15 mg [1].

Where they part company is the destination. The label states:

• For weight reduction and long-term maintenance, the recommended maintenance dosage is 5 mg, 10 mg or 15 mg
• For obstructive sleep apnea, the recommended maintenance dosage is 10 mg or 15 mg [1]

SURMOUNT-OSA escalated participants to a maximum tolerated dose of 10 mg or 15 mg, so the label mirrors the trial. People who tolerated 15 mg stayed on 15 mg; people who tolerated 10 mg but not 15 mg stayed on 10 mg [2].

The label does add a general caution that applies to both indications: consider treatment response and tolerability when selecting the maintenance dosage, and if a patient does not tolerate a maintenance dosage, consider a lower one [1]. What that means for any individual is a prescriber’s call.

Can Zepbound replace a CPAP machine?

This is the question the approval raised, and the label refuses to answer it. The exact sentence is worth quoting:

“The clinical studies for OSA did not evaluate the timing or appropriateness of PAP discontinuation in patients who were previously compliant with PAP therapy.” [1]

Study 6 was not a test of whether you can stop PAP. Participants stayed on their therapy throughout and suspended it for seven days only so the primary endpoint could be measured without the machine masking the result.

So the honest position is: the trial showed that Zepbound reduced apnea events substantially in people who used PAP and in people who did not, but it did not study what happens when someone who currently relies on PAP stops. That decision belongs to a sleep physician who can re-test you, and it is not something to act on from a drug label or an article.

It is also worth noting what “remission or mild non-symptomatic OSA” meant in the trials: an AHI under 5, or an AHI of 5 to 14 with an Epworth Sleepiness Scale score of 10 or less [1]. Roughly half of people on Zepbound in Study 6 hit that bar. Roughly half did not.

What are the risks?

Zepbound’s safety profile is the same regardless of which indication you are being treated for, because it is the same molecule at the same doses.

The label carries a boxed warning: in rats, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures, and it is unknown whether it does so in humans because the human relevance of that finding has not been determined [1]. Zepbound is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, anyone with Multiple Endocrine Neoplasia syndrome type 2, and anyone with a known serious hypersensitivity to tirzepatide or its ingredients [1].

Other warnings in the label include severe gastrointestinal reactions, acute kidney injury from dehydration, acute gallbladder disease, acute pancreatitis, hypersensitivity reactions, hypoglycemia (especially alongside insulin or a sulfonylurea), worsening of existing diabetic retinopathy in people with type 2 diabetes, and the risk of food entering the lungs during procedures using anesthesia or deep sedation [1].

The most common side effects in the weight-management trials were nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, hypersensitivity reactions, belching, hair loss and heartburn [1].

One indication-specific detail: the label notes that the rate of adjudication-confirmed pancreatitis in the pooled OSA studies was 0.84 patients per 100 years of exposure on Zepbound versus zero on placebo — a small number of events, but a higher rate than was seen in the weight-management trials [1].

Two 2026 label changes are relevant. In February 2026 FDA approved removal of the suicidal ideation and behavior warning from the Zepbound label following its review of a class-wide signal, and at the same time added intestinal obstruction and severe constipation including fecal impaction to the postmarketing experience section [1].

Will insurance cover Zepbound for sleep apnea?

Coverage is decided plan by plan, and many plans treat the sleep apnea indication differently from the weight-management one. Lilly’s own coverage checker asks which condition you are being treated for before returning an estimate, which tells you something about how much it varies [4].

The channels available are the same as for weight management [5]:

• Commercial insurance that covers Zepbound. The single-dose pen savings card can bring eligible patients to as little as $25 a month for up to a three-month prescription, subject to a $100 monthly and $1,300 annual savings cap (verified 2026-09-14). This is a savings-card tier, not a self-pay price.
• Self-pay. Zepbound single-dose vials and KwikPens cost $299 to $449 a month through LillyDirect depending on strength and refill timing. Since both OSA maintenance doses are 10 mg or 15 mg, the relevant figure is $449 a month with a refill inside 45 days. Without it, the regular price Lilly publishes today is $699 at both 10 mg and 15 mg [8]. Lilly’s December 2025 announcement put the 15 mg regular price at $1,049; that figure has been superseded.
• Medicare. The Medicare GLP-1 Bridge program (July 1, 2026 to December 31, 2027) caps cost at $50 a month for eligible Part D enrollees, but CMS frames it as a weight-loss benefit with BMI-based eligibility, and for Zepbound it covers the KwikPen only — not the single-dose pen and not vials [7]. Nothing CMS or Lilly publishes says an obstructive sleep apnea prescription qualifies on its own, so confirm with your plan before assuming it does.

Lilly also runs separate support materials for the sleep apnea indication, including a distinct digital starter kit reachable by texting “ZO” to 85099, alongside the general Lilly Health app [6].

Who is this approval actually for?

Reading the label plainly, the person it describes is an adult with obesity and moderate-to-severe obstructive sleep apnea confirmed by a sleep study, who is either unable or unwilling to use PAP therapy, or who is using it and wants to address the underlying driver as well. It is not for people with mild sleep apnea, for people with sleep apnea at a normal weight, for central sleep apnea, or for children.

And it sits alongside PAP rather than obviously replacing it, because the question of replacement was never studied.

If you snore heavily, wake unrefreshed, or have been told you stop breathing at night, the first step is not a prescription — it is a sleep study, because the indication is written around a number only a sleep study can produce.

Sources

1. ZEPBOUND (tirzepatide) injection — US Prescribing Information, revised 8/2026 (DailyMed). Sections 1, 2.1, 2.2, 5, 6 and 14.2 including Tables 8 and 9
2. FDA approves Zepbound as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity — Eli Lilly, December 20, 2024
3. Drugs@FDA: NDA 217806 (Zepbound) approval history
4. Savings and Insurance Options — Zepbound (tirzepatide)
5. Authentic Zepbound (tirzepatide) Shipped to You — LillyDirect
6. Resources, Support, Tips and Guides — Zepbound (tirzepatide)
7. Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month (CMS Product No. 12234, June 2026)
8. Lilly lowers the price of Zepbound (tirzepatide) single-dose vials — Eli Lilly, December 1, 2025